Drug intelligence / Profile preview

anthracycline + cyclophosphamide + vincristine

Development stage
Unknown
Lead developer
Takeda
Modality
DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
Administration
Intravenous, Oral
01

Overview

This is a combination chemotherapy regimen consisting of an anthracycline (such as doxorubicin or daunorubicin), cyclophosphamide, and vincristine. Each component has a distinct mechanism of action: - Anthracyclines (e.g., doxorubicin, daunorubicin) are cytotoxic antibiotics that intercalate DNA and inhibit topoisomerase II, leading to DNA damage and apoptosis in rapidly dividing cells. - Cyclophosphamide is an alkylating agent that crosslinks DNA strands, preventing cell division and leading to cell death. - Vincristine is a vinca alkaloid that inhibits microtubule formation in mitosis, arresting cells in metaphase. This combination targets cancer cells at different points in the cell cycle for synergistic antineoplastic effects. It has been used as part of various regimens for hematologic malignancies such as lymphomas and leukemias[5][7]. The specific anthracycline used may vary depending on the protocol.

02

Targets

TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))DNA

Beyond the preview

Go deeper on anthracycline + cyclophosphamide + vincristine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on anthracycline + cyclophosphamide + vincristine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call